| Nilofer Saba Azad | |
| Fields: | Oncology |
| Workplaces: | Johns Hopkins University |
| Alma Mater: | Baylor College of Medicine |
Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Azad earned a M.D. at Baylor College of Medicine in 2001. She completed a residency in internal medicine at Baylor in 2004 and a fellowship in oncology and hematology at the National Cancer Institute (NCI) in 2008. Azad was certified in medical oncology by the American Board of Internal Medicine in 2007.[1]
Azad joined the Sidney Kimmel Comprehensive Cancer Center (SKCCC) in 2008. She is a professor of oncology at Johns Hopkins School of Medicine. At the SKCCC, Azad serves as co-director of the Developmental Therapeutics Clinical Research Program and the Cancer Genetic and Epigenetic Core Research Program. Azad specializes in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She researches the development of therapeutics and oversees clinical trials using epigenetic therapy, chemotherapy, and cancer immunotherapy. She is a member of both the Epigenetics and Colon Cancer Stand Up 2 Cancer Dream Teams, serving as a Principal on the latter, and has held multiple leadership positions in national and international organizations.
In September 2021, Azad was appointed by U.S. president Joe Biden to serve on the NCI National Cancer Advisory Board.[2]
She speaks English and Hindustani.